Unravelling the Mystery of Long COVID: HIQA Reviews Potential Interventions

By HEOR Staff Writer

July 31, 2023

HIQA continues to lead the charge in understanding and managing Long COVID. Their latest systematic review explores potential interventions aimed at improving the varied and often debilitating symptoms of this complex condition. While no definitive treatments have been identified yet, their research continue.

The review included 57 randomised controlled trials of interventions for adults with Long COVID symptoms, typically in people with less than a year’s duration and no pre-existing chronic illnesses. The studies varied in intervention type and were generally short-term, with small sample sizes and not enough focus on specific subpopulations like older adults or those with chronic conditions. There was also insufficient examination of intervention safety. The interventions proposed in this review for Long COVID symptoms lack sufficient evidence for their effectiveness. Personalised exercise and physiotherapy involving breathing exercises may have short-term benefits, but their long-term effects were not assessed. More research is needed to investigate the effectiveness and safety of other treatments, and a greater understanding of Long COVID’s pathophysiology could help design targeted interventions. In the absence of strong evidence, a holistic approach is recommended to support those living with Long COVID.

Reference url

Recent Posts

large language models
Large Language Models in Evidence-Based Medicine

By João L. Carapinha

July 3, 2026

Large language models deliver rapid synthesis of medical literature, but according to research on fast information and slow evidence, they cannot independently generate validated evidence for clinical decisions. These tools sit at a...
African Pharmacogenomic Integration
African Pharmacogenomic Integration Enhancing Essential Medicine Prescribing in Africa

By João L. Carapinha

July 3, 2026

African Pharmacogenomic Integration has become an urgent policy priority, with evidence showing that more than 10 percent of essential medicines across Africa require genetically guided prescribing to prevent harm and improve outcomes in diverse populations. Current dosage guidelines for HIV, ...
Portugal Biotech Growth
Catalysts Driving Portugal Biotech Growth in Europe

By João L. Carapinha

July 2, 2026

Portugal Biotech Growth is reshaping the country’s standing in European life sciences, delivering a compact yet high-potential ecosystem anchored by world-class universities in Porto and Coimbra, innovation parks, and forward-looking industrial policy. Once overshadowed by larger neighbours, Port...